During the past decade, Harzklinikum Dorothea Christiane Erxleben GmbH conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Harzklinikum Dorothea Christiane Erxleben GmbH" #1 sponsor was "Abbott Medical Devices" with 5 trials, followed by "Daiichi Sankyo, Inc." with 2 trials sponsored, "AGO Research GmbH" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "EuMelaReg gGmbH" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Harzklinikum Dorothea Christiane Erxleben GmbH" #1 collaborator was "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Australia New Zealand Gynaecological Oncology Group" with 1 trials as a collaborator, "Daiichi Sankyo Deutschland GmbH" with 1 trials as a collaborator and "ICON plc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Harzklinikum Dorothea Christiane Erxleben GmbH" are "Atrial Fibrillation" (3 trials), "Basal Cell Carcinoma" (2 trials), "Heart Failure" (2 trials), "Brain Metastases" (1 trials) and "Cardiac Arrhythmias" (1 trials). Many other conditions were trialed in "Harzklinikum Dorothea Christiane Erxleben GmbH" in a lesser frequency.

Most popular intervention types in "Harzklinikum Dorothea Christiane Erxleben GmbH" are "Drug" (6 trials), "Device" (5 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Edoxaban" (2 trials), "Bevacizumab" (1 trials), "CRT-P indicated patients" (1 trials), "Carboplatin" (1 trials) and "Confirm Rx ICM insertion procedure" (1 trials). Other intervention names were less common.

The vast majority of trials in "Harzklinikum Dorothea Christiane Erxleben GmbH" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Harzklinikum Dorothea Christiane Erxleben GmbH". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Harzklinikum Dorothea Christiane Erxleben GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Harzklinikum Dorothea Christiane Erxleben GmbH, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".